Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Free Radic Biol Med ; 212: 199-206, 2024 02 20.
Article in English | MEDLINE | ID: mdl-38103659

ABSTRACT

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, leading to liver steatosis, fibrosis, and hepatocellular carcinoma (HCC). Despite the accumulation of clinical data showing the impact of amino acid substitutions at positions 70 (R70Q/H) and/or 91 (L91M) in the HCV core protein in progressive liver diseases, including HCC, the underlying mechanisms have not been elucidated. We analyzed 72 liver biopsy specimens from patients with chronic HCV genotype 1b (HCV-1b) infection prior to antiviral treatment. Levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG) and nuclear factor erythroid 2-related factor 2 (NRF2) in the nucleus were quantified using liver tissue immunohistochemistry. The effects of amino acid substitutions in the HCV core region on hepatocellular oxidative stress were investigated using wild-type or double-mutant (R70Q/H+L91M) HCV-1b core transfection and stable expression in human hepatoma HuH-7 cells. Overall, 24, 19, 11, and 18 patients had the wild-type, R70Q/H, L91M, and R70Q/H+L91M genotypes, respectively, in the HCV core. A significantly higher accumulation of hepatocellular 8-OHdG and a lower NRF2/8-OHdG ratio were observed in patients with R70Q/H+L91M than in those with the wild-type disease. Increased levels of intracellular superoxide and hydrogen peroxide in the cytoplasm and mitochondria, mRNA expression of enzymes generating oxidative stress, and nuclear expression of nicotinamide adenine dinucleotide phosphate oxidase 4 were augmented in cells treated with R70Q+L91M. HCV core proteins harboring either or both substitutions of R70Q/H or L91M enhanced hepatocellular oxidative stress in vivo and in vitro. These amino acid substitutions may affect HCC development by enhancing hepatic oxidative stress in patients with chronic HCV-1b infection.


Subject(s)
Carcinoma, Hepatocellular , Hepatitis C, Chronic , Hepatitis C , Liver Neoplasms , Humans , Carcinoma, Hepatocellular/pathology , Hepacivirus/genetics , Liver Neoplasms/pathology , Amino Acid Substitution , NF-E2-Related Factor 2/genetics , Hepatitis C/genetics , Hepatitis C, Chronic/genetics , Oxidative Stress/genetics , 8-Hydroxy-2'-Deoxyguanosine , Viral Core Proteins/genetics , Viral Core Proteins/pharmacology , Viral Core Proteins/therapeutic use , Genotype
2.
Microbiol Spectr ; 10(3): e0034522, 2022 06 29.
Article in English | MEDLINE | ID: mdl-35579445

ABSTRACT

How the hepatitis C virus (HCV) core antigen (HCVcAg) assay performs in detecting recently acquired HCV infection among people living with HIV (PLWH) and HIV-negative men who have sex with men (MSM) is rarely assessed in the Asia-Pacific region. High-risk participants, including PLWH with sexually transmitted infections (STIs), HCV clearance by antivirals or spontaneously, or elevated aminotransferases, HIV-negative MSM with STIs or on HIV preexposure prophylaxis, and low-risk PLWH were enrolled. Blood samples were subjected to 3-stage pooled-plasma HCV RNA testing every 3 to 6 months until detection of HCV viremia or completion of the 1-year follow-up. The samples at enrollment and all of the archived samples preceding the detection of HCV RNA during follow-up were tested for HCVcAg. During June 2019 and February 2021, 1,639 blood samples from 744 high-risk and 727 low-risk PLWH and 86 HIV-negative participants were tested for both HCV RNA and HCVcAg. Of 62 samples positive for HCV RNA, 54 (87.1%) were positive for HCVcAg. Of 1,577 samples negative for HCV RNA, 1,568 (99.4%) were negative for HCVcAg. The mean HCV RNA load of the 8 individual samples positive for HCV RNA but negative for HCVcAg was 3.2 (range, 2.5 to 3.9) log10 IU/mL, and that of the remaining 54 samples with concordant results was 6.2 (range, 1.3 to 8.5) log10 IU/mL. The positive predictive value (PPV) and negative predictive value (NPV) of HCVcAg were 85.7% and 99.5%, respectively. In at-risk populations, HCVcAg has a high specificity and NPV but lower sensitivity and PPV, particularly in individuals with low HCV RNA loads. IMPORTANCE The HCV core antigen assay has a high specificity of 99.4% and negative predictive value of 99.5% but a lower sensitivity of 87.1% and positive predictive value of 85.7% in the diagnosis of recently acquired HCV infection in high-risk populations. Our findings are informative for many countries confronted with limited resources to timely identify acute HCV infections and provide effective direct-acting antivirals to halt onward transmission.


Subject(s)
HIV Infections , Hepatitis C, Chronic , Hepatitis C , Sexual and Gender Minorities , Antiviral Agents/therapeutic use , HIV Infections/diagnosis , HIV Infections/drug therapy , Hepacivirus/genetics , Hepatitis C/drug therapy , Hepatitis C Antigens/genetics , Hepatitis C Antigens/therapeutic use , Hepatitis C, Chronic/diagnosis , Homosexuality, Male , Humans , Male , RNA, Viral/genetics , Sensitivity and Specificity , Viral Core Proteins/genetics , Viral Core Proteins/therapeutic use
3.
Clin Vaccine Immunol ; 17(7): 1139-47, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20519445

ABSTRACT

In this study, the effects of wild-type and deletion mutant hepatitis C virus (HCV) core proteins on the induction of immune responses in BALB/c mice were assessed. p2HA-C145-S23, encoding a core protein with the C-terminal 46 amino acids truncated, significantly produced stronger antibody and cellular responses than p2HA-C191-S23. The induction of immune responses by p2HA-C145-S23 was dose dependent. However, increasing the doses or repeated administration did not enhance immune responses by the wild-type core protein. In addition, p2HA-C191-S23 was apparently able to interfere with the priming of specific immune responses by p2HA-C145-S23 when the two were coadministered. These results demonstrated that the wild-type HCV core protein itself could inhibit the priming of immune responses in the course of a DNA vaccination, whereas the truncated HCV core protein could provide potential applications for the development of DNA- and peptide-based HCV vaccines.


Subject(s)
Antigens, Viral/therapeutic use , B-Lymphocytes/immunology , Hepacivirus/immunology , T-Lymphocytes/immunology , Viral Core Proteins/therapeutic use , Animals , Antigens, Viral/administration & dosage , Antigens, Viral/immunology , Immunity , Mice , Mice, Inbred BALB C , Vaccines, DNA , Viral Core Proteins/administration & dosage , Viral Core Proteins/immunology , Viral Vaccines
4.
Eur J Pharm Sci ; 13(1): 61-9, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11292569

ABSTRACT

The liposomally encapsulated and the free antisense phosphorothioate oligonucleotides (S-ODNs) with four target sites (PB1, PB2, PA, and NP) were tested for their abilities to inhibit virus-induced cytopathogenic effects by a MTT assay using MDCK cells. The liposomally encapsulated S-ODN complementary to the sites of the PB2-AUG initiation codon showed highly inhibitory effects. On the other hand, the inhibitory effect of the liposomally encapsulated S-ODN targeted to PB1 was considerably decreased in comparison with those directed to the PB2 target sites. The liposomally encapsulated antisense phosphorothioate oligonucleotides exhibited higher inhibitory activities than the free oligonucleotides, and showed sequence-specific inhibition, whereas the free antisense phosphorothioate oligonucleotides were observed to inhibit viral absorption to MDCK cells. Therefore, the antiviral effects of S-ODN-PB2-AUG and PA-AUG were examined in a mouse model of influenza virus A infection. Balb/c mice exposed to the influenza virus A (A/PR/8/34) strain at dose of 100 LD(50)s were treated i.v. with various doses (5-40 mg/kg) of liposomally (Tfx-10) encapsulated PB2-AUG or PA-AUG before virus infection and 1 and 3 days postinfection. PB2-AUG oligomer treated i.v. significantly prolonged the mean survival time in days (MDS) and increased the survival rates with a dose-dependent manner. We demonstrate the first successful in vivo antiviral activity of antisense administered i.v. in experimental respiratory tract infections induced with influenza virus A.


Subject(s)
DNA-Directed RNA Polymerases/therapeutic use , Influenza A virus , Nucleoproteins , Oligonucleotides, Antisense/therapeutic use , Orthomyxoviridae Infections/drug therapy , RNA-Dependent RNA Polymerase , Viral Core Proteins/therapeutic use , Viral Proteins/therapeutic use , Animals , DNA-Directed RNA Polymerases/pharmacology , Influenza A virus/drug effects , Influenza A virus/pathogenicity , Liposomes , Mice , Mice, Inbred BALB C , Nucleocapsid Proteins , Oligonucleotides, Antisense/pharmacology , Viral Core Proteins/pharmacology , Viral Proteins/pharmacology
5.
J Gen Virol ; 80 ( Pt 6): 1393-1399, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10374956

ABSTRACT

The capacity of DNA vaccines to prime CD8+ T cells makes them excellent candidates for vaccines that are designed to emphasize cellular immunity. However, the long-term stability of CD8+ T cell memory induced by DNA vaccination is poorly characterized. Here, the quality of CD8+ T cell recall responses in mice was investigated more than 1 year after DNA vaccination with the Sendai virus nucleoprotein gene. Cytotoxic T lymphocyte (CTL) activity specific for both dominant and subdominant epitopes could be recalled readily 1 year after vaccination and the frequencies of CTL precursors specific for both of these epitopes were relatively high. These CTL responded strongly to subsequent Sendai virus infection in terms of their ability to migrate to the lung and to differentiate into effector cells. In addition, the recall response to virus infection, as determined by CTL activity in the lungs and IFN-gamma responses in the spleen, was both faster and greater in magnitude than that in control-immunized mice. Significantly, virus titres were reduced at least 100-fold in the lungs of mice that were immunized more than 1 year before infection, as compared with control mice. These data demonstrate that CD8+ T cell memory elicited by DNA vaccination is functionally relevant and persists for at least 1 year.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Immunologic Memory , Nucleoproteins , Respirovirus Infections/immunology , Respirovirus/immunology , Vaccines, DNA/immunology , Viral Vaccines/immunology , Animals , Female , Immunodominant Epitopes/immunology , Lung/virology , Mice , Mice, Inbred C57BL , Nucleocapsid Proteins , Respirovirus/growth & development , Respirovirus Infections/prevention & control , Respirovirus Infections/virology , T-Lymphocytes, Cytotoxic/immunology , Vaccination , Vaccines, DNA/administration & dosage , Viral Core Proteins/genetics , Viral Core Proteins/therapeutic use , Viral Vaccines/administration & dosage
6.
Scand J Immunol ; 28(1): 81-5, 1988 Jul.
Article in English | MEDLINE | ID: mdl-2456608

ABSTRACT

Influenza nucleoprotein (NP)-specific cytotoxic T lymphocytes (CTL) stimulated by immunization of mice with VV-PR8-NP6, a recombinant vaccinia virus expressing A/PR/8/34 NP, did not protect mice against challenge with A/PR/8/34 4 days later. Neither were secondary NP-specific CTL stimulated by reimmunization able to protect mice. These results contrast with the ability of transferred, in vitro-cultured and stimulated, NP-specific CTL to protect recipient mice from challenge with A/PR/8/34. Immunization of mice with a recombinant vaccinia virus expressing A/PR/8/34 HA protected mice challenged 4 days later, either via the small amount of antibody already present, or via HA-specific CTL that would have to be more efficient than NP-specific CTL in either trafficking to the infected lung or in effector function.


Subject(s)
Antigens, Viral/administration & dosage , Hemagglutinins, Viral/therapeutic use , Influenza A virus/immunology , Nucleoproteins , Orthomyxoviridae Infections/prevention & control , Viral Core Proteins/therapeutic use , Animals , Antibodies, Viral/biosynthesis , Epitopes/immunology , Hemagglutinin Glycoproteins, Influenza Virus , Hemagglutinins, Viral/immunology , Immunization, Secondary , Mice , Mice, Inbred CBA , Nucleocapsid Proteins , Orthomyxoviridae Infections/immunology , T-Lymphocytes, Cytotoxic/immunology , Viral Core Proteins/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...